Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial.
Saved in:
| Title: | Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial. |
|---|---|
| Authors: | Abdel Jawad, Mohammad1,2 (AUTHOR), Furtado, Remo H. M.3 (AUTHOR), Esterline, Russell4 (AUTHOR), Oscarsson, Jan5 (AUTHOR), Gasparyan, Samvel B.6 (AUTHOR), Koch, Gary G.7 (AUTHOR), Martinez, Felipe8 (AUTHOR), Mukhtar, Omar9 (AUTHOR), Verma, Subodh10,11,12 (AUTHOR), Langkilde, Anna Maria5 (AUTHOR), Ambery, Philip5 (AUTHOR), Patel, Shachi1,2 (AUTHOR), Gosch, Kensey1,2 (AUTHOR), Windsor, Sheryl L.1 (AUTHOR), Soares, Ronaldo V. P.13 (AUTHOR), Moia, Diogo D. F.13 (AUTHOR), Aboudara, Matthew14 (AUTHOR), Javaheri, Ali15 (AUTHOR), Saraiva, J. F. Kerr16 (AUTHOR), Maia, Lilia Nigro17 (AUTHOR) |
| Source: | Cardiovascular Diabetology. 7/30/2025, Vol. 24 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
